Physician profile
Timothy Vanfrank
NPI 1992775407
$1,398.98
in general payments reported to CMS, 2019-2025
11 companies · $563 in 2025
The $563 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $16.53 · 2021: $99.01 · 2022: $57.05 · 2023: $286 · 2024: $185 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.19 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $138.01 | 2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $55.66 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $47.63 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $36.69 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.40 | 2021-2025 | Xifaxan |
| Braintree Laboratories, INC. | $23.84 | 2021 | |
| Shionogi INC | $21.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.34 | 2024 | Voquezna |
| Shire North American Group INC | $14.14 | 2019 | |
| Conmed Corporation | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Vanfrank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.